Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evidence exists to support low-grade inflammation as the inciting factor leading to visceral hypersensitivity and alteration in motility in irritable bowel syndrome.In the medical literature,there is ample in vitro and in vivo evidence supporting turmeric and its derivative curcumin as an antitumor, anti-inflammatory and antioxidant agent. We propose a randomized, placebo-controlled, double blinded, parallel treatment study evaluating the effects of turmeric on the symptoms of irritable bowel syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Curcumin on Gut Microbiota in IBS

NCT03568513

Irritable Bowel Syndrome

COMPLETED NA

Postprandial Lipids in IBS and Nutritional Treatment

NCT05016596

IBS - Irritable Bowel Syndrome

COMPLETED NA

Curcumin, Vitamin D and Green Tea in IBS-D

NCT07052890

Irritable Bowel Syndrome (IBS) Irritable Bowel Syndrome With Diarrhea (IBS-D)

ACTIVE_NOT_RECRUITING NA

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526

Irritable Bowel Syndrome

COMPLETED PHASE2

Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS

NCT06187298

Irritable Bowel Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Curcumin 900mg twice daily by mouth

Group Type ACTIVE_COMPARATOR

curcumin

Intervention Type DIETARY_SUPPLEMENT

curcumin 900mg twice daily by mouth

B

Placebo capsule to be made by Swanson Vitamins to simulate the capsule.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DIETARY_SUPPLEMENT

placebo capsule to simulate 900mg curcumin capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

curcumin

curcumin 900mg twice daily by mouth

Intervention Type DIETARY_SUPPLEMENT

placebo

placebo capsule to simulate 900mg curcumin capsule

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Swanson vitamins-curcumin Swanson curcumin placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients from the hospitals and clinics of the Southern California Permanente Medical Group who conform to the Rome III criteria and

* Age 18 years and above,
* Male or female,
* Able to give consent and follow the treatment plan and be able to answer surveys.
* Negative serum pregnancy test (females of childbearing potential only) and are willing to use an adequate method of contraception throughout the duration of the study.

Exclusion Criteria

* Any of the following: diabetes, HIV disease, use of anticoagulants or antiplatelet medication, abnormal coagulation or thrombocytopenia, biliary obstruction, inflammatory bowel, symptomatic gallstones, celiac disease, ongoing use of medications known to cause or exacerbate symptoms of IBS and chronic, daily users of IBS medications.
* Use of scheduled IBS medications for 4 weeks prior to and during the treatment period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes